Cidara Therapeutics, Inc. announced on May 1, 2025, the promotion of Nicole Davarpanah, M.D., J.D., to Chief Medical Officer (CMO), and Corrina Pavetto to Senior Vice President, Clinical Development, effective May 1, 2025.
Dr. Davarpanah brings over a decade of clinical development and translational medicine experience, including leadership roles at Genentech/Roche. Her expertise in treating high-risk and immunocompromised patients is particularly valuable as Cidara prioritizes these populations for the Phase 3 development of CD388.
Ms. Pavetto has over 25 years of experience in clinical research and regulatory affairs, with a specialized focus on infectious disease, including supporting influenza antiviral and vaccine development at BARDA. These promotions are critical as Cidara advances its influenza antiviral candidate, CD388, through its Phase 2b NAVIGATE trial and plans for Phase 3.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.